

Kenneth A Freedberg

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/704150/publications.pdf>

Version: 2024-02-01

117
papers

4,729
citations

136740

32
h-index

106150

65
g-index

123
all docs

123
docs citations

123
times ranked

6021
citing authors

#	ARTICLE	IF	CITATIONS
1	Psychological Distress Increases 30-Fold Among People with HIV in the First Year on ART in Nigeria—a Call for Integrated Mental Health Services. <i>International Journal of Behavioral Medicine</i> , 2023, 30, 38-48.	0.8	3
2	Do not forget the children: a model-based analysis on the potential impact of COVID-19-associated interruptions in paediatric HIV prevention and care. <i>Journal of the International AIDS Society</i> , 2022, 25, e25864.	1.2	7
3	Cost-Effectiveness of Long-Acting Injectable HIV Preexposure Prophylaxis in the United States. <i>Annals of Internal Medicine</i> , 2022, 175, 479-489.	2.0	37
4	Cost-effectiveness of Routine Provider-Initiated Testing and Counseling for Children With Undiagnosed HIV in South Africa. <i>Open Forum Infectious Diseases</i> , 2022, 9, ofab603.	0.4	2
5	The cost-effectiveness of a resilience-based psychosocial intervention for HIV prevention among men who have sex with men in India. <i>Aids</i> , 2022, Publish Ahead of Print, .	1.0	1
6	Clearance of Hepatitis B e Antigen in Untreated Chronic Hepatitis B Virus Infection: A Systematic Review and Meta-analysis. <i>Journal of Infectious Diseases</i> , 2022, 226, 1761-1770.	1.9	2
7	Cost-effectiveness of Coronavirus Disease 2019 Vaccination in Low- and Middle-Income Countries. <i>Journal of Infectious Diseases</i> , 2022, 226, 1887-1896.	1.9	9
8	Risks and benefits of oral HIV pre-exposure prophylaxis for people with chronic hepatitis B. <i>Lancet HIV</i> , 2022, 9, e585-e594.	2.1	5
9	Cost-effectiveness of a Novel Lipoarabinomannan Test for Tuberculosis in Patients With Human Immunodeficiency Virus. <i>Clinical Infectious Diseases</i> , 2021, 73, e2077-e2085.	2.9	10
10	Cost-effectiveness of Frequent HIV Screening Among High-risk Young Men Who Have Sex With Men in the United States. <i>Clinical Infectious Diseases</i> , 2021, 73, e1927-e1935.	2.9	7
11	Clinical Impact, Costs, and Cost-effectiveness of Expanded Severe Acute Respiratory Syndrome Coronavirus 2 Testing in Massachusetts. <i>Clinical Infectious Diseases</i> , 2021, 73, e2908-e2917.	2.9	52
12	Cost-effectiveness of public health strategies for COVID-19 epidemic control in South Africa: a microsimulation modelling study. <i>The Lancet Global Health</i> , 2021, 9, e120-e129.	2.9	71
13	College Campuses and COVID-19 Mitigation: Clinical and Economic Value. <i>Annals of Internal Medicine</i> , 2021, 174, 472-483.	2.0	64
14	Optimizing infant HIV diagnosis with additional screening at immunization clinics in three sub-Saharan African settings: a cost-effectiveness analysis. <i>Journal of the International AIDS Society</i> , 2021, 24, e25651.	1.2	5
15	Modeling Adherence Interventions Among Youth with HIV in the United States: Clinical and Economic Projections. <i>AIDS and Behavior</i> , 2021, 25, 2973-2984.	1.4	5
16	Evaluating Point-of-Care Nucleic Acid Tests in Adult Human Immunodeficiency Virus Diagnostic Strategies: A CÃte d'Ivoire Modeling Analysis. <i>Open Forum Infectious Diseases</i> , 2021, 8, ofab225.	0.4	0
17	Clinical outcomes and cost-effectiveness of COVID-19 vaccination in South Africa. <i>Nature Communications</i> , 2021, 12, 6238.	5.8	31
18	âœCureâœVersus âœClinical Remissionâœ: The Impact of a Medication Description on the Willingness of People Living with HIV to Take a Medication. <i>AIDS and Behavior</i> , 2020, 24, 2054-2061.	1.4	7

#	ARTICLE	IF	CITATIONS
19	Comparative Pricing of Branded Tenofovir Alafenamide–Emtricitabine Relative to Generic Tenofovir Disoproxil Fumarate–Emtricitabine for HIV Preexposure Prophylaxis. <i>Annals of Internal Medicine</i> , 2020, 173, 507-508.	2.0	4
20	Comparative Pricing of Branded Tenofovir Alafenamide–Emtricitabine Relative to Generic Tenofovir Disoproxil Fumarate–Emtricitabine for HIV Preexposure Prophylaxis. <i>Annals of Internal Medicine</i> , 2020, 172, 583-590.	2.0	40
21	Developing and Validating Metamodels of a Microsimulation Model of Infant HIV Testing and Screening Strategies Used in a Decision Support Tool for Health Policy Makers. <i>MDM Policy and Practice</i> , 2020, 5, 238146832093289.	0.5	6
22	Strengthening Existing Laboratory-Based Systems vs. Investing in Point-of-Care Assays for Early Infant Diagnosis of HIV: A Model-Based Cost-Effectiveness Analysis. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2020, 84, S12-S21.	0.9	12
23	Comparative Effectiveness of Interventions to Improve the HIV Continuum of Care and HIV Preexposure Prophylaxis in Kenya: A Model-Based Analysis. <i>Journal of Infectious Diseases</i> , 2020, , .	1.9	0
24	Novel microsimulation model of tobacco use behaviours and outcomes: calibration and validation in a US population. <i>BMJ Open</i> , 2020, 10, e032579.	0.8	7
25	A novel method to estimate the indirect community benefit of HIV interventions using a microsimulation model of HIV disease. <i>Journal of Biomedical Informatics</i> , 2020, 107, 103475.	2.5	5
26	Waiting for Certainty on Covid-19 Antibody Tests – At What Cost?. <i>New England Journal of Medicine</i> , 2020, 383, e37.	13.9	80
27	The Challenges of Parameterizing Direct Effects in Individual-Level Simulation Models. <i>Medical Decision Making</i> , 2020, 40, 106-111.	1.2	7
28	Clinical and Economic Impact of Ibalizumab for People With Multidrug-Resistant HIV in the United States. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2020, 83, 148-156.	0.9	14
29	Clinical Outcomes, Costs, and Cost-effectiveness of Strategies for Adults Experiencing Sheltered Homelessness During the COVID-19 Pandemic. <i>JAMA Network Open</i> , 2020, 3, e2028195.	2.8	48
30	The impact of user fees on uptake of HIV services and adherence to HIV treatment: Findings from a large HIV program in Nigeria. <i>PLoS ONE</i> , 2020, 15, e0238720.	1.1	7
31	Cost-effectiveness and budget impact of immediate antiretroviral therapy initiation for treatment of HIV infection in Côte d'Ivoire: A model-based analysis. <i>PLoS ONE</i> , 2019, 14, e0219068.	1.1	5
32	Rapid, point-of-care diagnosis of tuberculosis with novel Truenat assay: Cost-effectiveness analysis for India's public sector. <i>PLoS ONE</i> , 2019, 14, e0218890.	1.1	37
33	Using national laboratory data to assess cumulative frequency of linkage after transfer to community-based HIV clinics in South Africa. <i>Journal of the International AIDS Society</i> , 2019, 22, e25326.	1.2	9
34	Effect of PEPFAR funding policy change on HIV service delivery in a large HIV care and treatment network in Nigeria. <i>PLoS ONE</i> , 2019, 14, e0221809.	1.1	22
35	Subclinical tuberculosis among adults with HIV: clinical features and outcomes in a South African cohort. <i>BMC Infectious Diseases</i> , 2019, 19, 14.	1.3	22
36	Cost-effectiveness of urine-based tuberculosis screening in hospitalised patients with HIV in Africa: a microsimulation modelling study. <i>The Lancet Global Health</i> , 2019, 7, e200-e208.	2.9	32

#	ARTICLE	IF	CITATIONS
37	Prevention of Prescription Opioid Misuse and Projected Overdose Deaths in the United States. JAMA Network Open, 2019, 2, e187621.	2.8	220
38	HIV testing in a large community health center serving a multi-cultural patient population: A qualitative study of providers. AIDS Care - Psychological and Socio-Medical Aspects of AIDS/HIV, 2019, 31, 1585-1592.	0.6	2
39	Cost-effectiveness of integrating buprenorphine-naloxone treatment for opioid use disorder into clinical care for persons with HIV/hepatitis C co-infection who inject opioids. International Journal of Drug Policy, 2019, 72, 160-168.	1.6	23
40	Clinical effect and cost-effectiveness of incorporation of point-of-care assays into early infant HIV diagnosis programmes in Zimbabwe: a modelling study. Lancet HIV, 2019, 6, e182-e190.	2.1	36
41	Cost-effectiveness of a Medical Care Coordination Program for People With HIV in Los Angeles County. Open Forum Infectious Diseases, 2019, 6, ofz537.	0.4	6
42	Cost-effectiveness of integrating postpartum antiretroviral therapy and infant care into maternal & child health services in South Africa. PLoS ONE, 2019, 14, e0225104.	1.1	10
43	Cost of an HIV Medical Care Coordination Program in Los Angeles County. Journal of Acquired Immune Deficiency Syndromes (1999), 2019, 81, e15-e17.	0.9	2
44	Model-Based Methods to Translate Adolescent Medicine Trials Network for HIV/AIDS Interventions Findings Into Policy Recommendations: Rationale and Protocol for a Modeling Core (ATN 161). JMIR Research Protocols, 2019, 8, e9898.	0.5	6
45	What risk of death would people take to be cured of HIV and why? A survey of people living with HIV. Journal of Virus Eradication, 2019, 5, 109-115.	0.3	6
46	Optimal breastfeeding durations for HIV-exposed infants: the impact of maternal ART use, infant mortality and replacement feeding risk. Journal of the International AIDS Society, 2018, 21, e25107.	1.2	10
47	The cost-effectiveness and budgetary impact of a dolutegravir-based regimen as first-line treatment of HIV infection in India. Journal of the International AIDS Society, 2018, 21, e25085.	1.2	17
48	The Optimal Age for Screening Adolescents and Young Adults Without Identified Risk Factors for HIV. Journal of Adolescent Health, 2018, 62, 22-28.	1.2	23
49	The cost-effectiveness of HIV pre-exposure prophylaxis in men who have sex with men and transgender women at high risk of HIV infection in Brazil. Journal of the International AIDS Society, 2018, 21, e25096.	1.2	24
50	High Medication Possession Ratios Associated With Greater Risk of Virologic Failure Among Youth Compared With Adults in a Nigerian Cohort. Journal of Acquired Immune Deficiency Syndromes (1999), 2018, 78, 322-328.	0.9	7
51	Clinical Benefits and Cost-Effectiveness of Laboratory Monitoring Strategies to Guide Antiretroviral Treatment Switching in India. AIDS Research and Human Retroviruses, 2018, 34, 486-497.	0.5	2
52	Using Observational Data to Calibrate Simulation Models. Medical Decision Making, 2018, 38, 212-224.	1.2	10
53	1269. HIV Testing in a Large Community Health Center Serving a Multi-cultural Population: A Qualitative Study of Providers. Open Forum Infectious Diseases, 2018, 5, S387-S387.	0.4	0
54	HIV Testing After a First Positive Rapid Diagnostic Test: A Role for Nucleic Acid Testing?. Open Forum Infectious Diseases, 2018, 5, ofy170.	0.4	4

#	ARTICLE	IF	CITATIONS
55	Voluntary Community Human Immunodeficiency Virus Testing, Linkage, and Retention in Care Interventions in Kenya: Modeling the Clinical Impact and Cost-effectiveness. <i>Clinical Infectious Diseases</i> , 2018, 67, 719-726.	2.9	4
56	Lung Cancer Mortality Associated With Smoking and Smoking Cessation Among People Living With HIV in the United States. <i>JAMA Internal Medicine</i> , 2017, 177, 1613.	2.6	99
57	The patient-centered medical home: a reality for HIV care in Nigeria. <i>International Journal for Quality in Health Care</i> , 2017, 29, 654-661.	0.9	5
58	Do Less Harm: Evaluating HIV Programmatic Alternatives in Response to Cutbacks in Foreign Aid. <i>Annals of Internal Medicine</i> , 2017, 167, 618.	2.0	18
59	Foreign-born status as a predictor of engagement in HIV care in a large US metropolitan health system. <i>AIDS Care - Psychological and Socio-Medical Aspects of AIDS/HIV</i> , 2017, 29, 244-251.	0.6	22
60	Impact of Unplanned Care Interruption on CD4 Response Early After ART Initiation in a Nigerian Cohort. <i>Journal of the International Association of Providers of AIDS Care</i> , 2017, 16, 98-104.	0.6	7
61	Clinic-Based Urinary Lipoarabinomannan as a Biomarker of Clinical Disease Severity and Mortality Among Antiretroviral Therapy-Naive Human Immunodeficiency Virus-Infected Adults in South Africa. <i>Open Forum Infectious Diseases</i> , 2017, 4, ofx167.	0.4	11
62	Cost Effectiveness and Cost Containment in the Era of Interferon-Free Therapies to Treat Hepatitis C Virus Genotype 1. <i>Open Forum Infectious Diseases</i> , 2017, 4, ofw266.	0.4	14
63	The value of confirmatory testing in early infant HIV diagnosis programmes in South Africa: A cost-effectiveness analysis. <i>PLoS Medicine</i> , 2017, 14, e1002446.	3.9	30
64	Hepatitis C Testing Increased Among Baby Boomers Following The 2012 Change To CDC Testing Recommendations. <i>Health Affairs</i> , 2017, 36, 2142-2150.	2.5	34
65	Impact of Medication Adherence on Virologic Failure in A5202: A Randomized, Partially Blinded, Phase 3B Study. <i>Clinical Infectious Diseases</i> , 2017, 64, 1612-1614.	2.9	6
66	Survival benefits of antiretroviral therapy in Brazil: a model-based analysis. <i>Journal of the International AIDS Society</i> , 2016, 19, 20623.	1.2	19
67	The Anticipated Clinical and Economic Effects of 90-90-90 in South Africa. <i>Annals of Internal Medicine</i> , 2016, 165, 325.	2.0	36
68	Potential Clinical and Economic Value of Long-Acting Preexposure Prophylaxis for South African Women at High-Risk for HIV Infection. <i>Journal of Infectious Diseases</i> , 2016, 213, 1523-1531.	1.9	39
69	Age Matters: Increased Risk of Inconsistent HIV Care and Viremia Among Adolescents and Young Adults on Antiretroviral Therapy in Nigeria. <i>Journal of Adolescent Health</i> , 2016, 59, 298-304.	1.2	20
70	Clinical outcomes of HIV care delivery models in the US: a systematic review. <i>AIDS Care - Psychological and Socio-Medical Aspects of AIDS/HIV</i> , 2016, 28, 1215-1222.	0.6	22
71	High rates of unplanned interruptions from HIV care early after antiretroviral therapy initiation in Nigeria. <i>BMC Infectious Diseases</i> , 2015, 15, 397.	1.3	13
72	Cost-effectiveness of first-line antiretroviral therapy for HIV-infected African children less than 3 years of age. <i>Aids</i> , 2015, 29, 1247-1259.	1.0	33

#	ARTICLE	IF	CITATIONS
73	The Clinical Role and Cost-Effectiveness of Long-Acting Antiretroviral Therapy. <i>Clinical Infectious Diseases</i> , 2015, 60, 1102-1110.	2.9	41
74	HIV testing rates, prevalence, and knowledge among outpatients in Durban, South Africa: Time trends over four years. <i>International Journal of STD and AIDS</i> , 2015, 26, 704-709.	0.5	3
75	Cost-Effectiveness of Genotype Testing for Primary Resistance in Brazil. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2015, 68, 152-161.	0.9	11
76	The Lifetime Medical Cost Savings From Preventing HIV in the United States. <i>Medical Care</i> , 2015, 53, 293-301.	1.1	94
77	Finding HIV in Hard to Reach Populations: Mobile HIV Testing and Geospatial Mapping in Umlazi Township, Durban, South Africa. <i>AIDS and Behavior</i> , 2015, 19, 1888-1895.	1.4	33
78	Cost-effectiveness of CYP2B6 genotyping to optimize efavirenz dosing in HIV clinical practice. <i>Pharmacogenomics</i> , 2015, 16, 2007-2018.	0.6	19
79	Prenatal Transmission of Syphilis and Human Immunodeficiency Virus in Brazil: Achieving Regional Targets for Elimination. <i>Open Forum Infectious Diseases</i> , 2015, 2, ofv073.	0.4	9
80	Point-of-Care CD4 Testing to Inform Selection of Antiretroviral Medications in South African Antenatal Clinics: A Cost-Effectiveness Analysis. <i>PLoS ONE</i> , 2015, 10, e0117751.	1.1	12
81	The HIV Cure Research Agenda: The Role of Mathematical Modelling and Cost-Effectiveness Analysis. <i>Journal of Virus Eradication</i> , 2015, 1, 245-249.	0.3	7
82	Mobile HIV Screening in Cape Town, South Africa: Clinical Impact, Cost and Cost-Effectiveness. <i>PLoS ONE</i> , 2014, 9, e85197.	1.1	45
83	Development, Calibration and Performance of an HIV Transmission Model Incorporating Natural History and Behavioral Patterns: Application in South Africa. <i>PLoS ONE</i> , 2014, 9, e98272.	1.1	20
84	The Patient-Centered Medical Home: A Reality for HIV Care in Nigeria. <i>Open Forum Infectious Diseases</i> , 2014, 1, S412-S413.	0.4	0
85	Effectiveness of first-line antiretroviral therapy in the IPEC cohort, Rio de Janeiro, Brazil. <i>AIDS Research and Therapy</i> , 2014, 11, 29.	0.7	14
86	Misinterpretation of HIV Preexposure Prophylaxis Findings. <i>Clinical Infectious Diseases</i> , 2014, 59, 139-141.	2.9	0
87	The Clinical and Economic Impact of Point-of-Care CD4 Testing in Mozambique and Other Resource-Limited Settings: A Cost-Effectiveness Analysis. <i>PLoS Medicine</i> , 2014, 11, e1001725.	3.9	48
88	The Linkage Outcomes of a Large-scale, Rapid Transfer of HIV-infected Patients From Hospital-based to Community-based Clinics in South Africa. <i>Open Forum Infectious Diseases</i> , 2014, 1, ofu058.	0.4	22
89	Individualizing the WHO HIV and infant feeding guidelines. <i>Aids</i> , 2014, 28, S287-S299.	1.0	7
90	Diagnostic point-of-care tests in resource-limited settings. <i>Lancet Infectious Diseases</i> , The, 2014, 14, 239-249.	4.6	525

#	ARTICLE	IF	CITATIONS
91	The Impact of the 2013 WHO Antiretroviral Therapy Guidelines on the Feasibility of HIV Population Prevention Trials. <i>HIV Clinical Trials</i> , 2014, 15, 185-198.	2.0	6
92	HIV Cure Strategies: How Good Must They Be to Improve on Current Antiretroviral Therapy?. <i>PLoS ONE</i> , 2014, 9, e113031.	1.1	21
93	Cost-Effectiveness of HIV Treatment as Prevention in Serodiscordant Couples. <i>New England Journal of Medicine</i> , 2013, 369, 1715-1725.	13.9	122
94	Validation and Calibration of a Computer Simulation Model of Pediatric HIV Infection. <i>PLoS ONE</i> , 2013, 8, e83389.	1.1	29
95	Routine HIV Screening in Portugal: Clinical Impact and Cost-Effectiveness. <i>PLoS ONE</i> , 2013, 8, e84173.	1.1	32
96	Cost-effectiveness of Adding an Agent That Improves Immune Responses to Initial Antiretroviral Therapy (ART) in HIV-Infected Patients: Guidance for Drug Development. <i>HIV Clinical Trials</i> , 2012, 13, 1-10.	2.0	8
97	WHO 2010 Guidelines for Prevention of Mother-to-Child HIV Transmission in Zimbabwe: Modeling Clinical Outcomes in Infants and Mothers. <i>PLoS ONE</i> , 2011, 6, e20224.	1.1	41
98	Medication Possession Ratio: Predicting and Decreasing Loss to Follow-Up in Antiretroviral Treatment Programs in CÔte d'Ivoire. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2011, 57, S34-S39.	0.9	16
99	HIV type-1 clade C resistance genotypes in treatment-naïve patients and after first virological failure in a large community antiretroviral therapy programme. <i>Antiviral Therapy</i> , 2009, 14, 523-531.	0.6	79
100	Clinical impact and cost-effectiveness of antiretroviral therapy in India: starting criteria and second-line therapy. <i>Aids</i> , 2007, 21, S117-S128.	1.0	48
101	Impact of Expanded HIV Screening. <i>Annals of Internal Medicine</i> , 2007, 147, 146.	2.0	0
102	The Independent Effect of Highly Active Antiretroviral Therapy on Severe Opportunistic Disease Incidence and Mortality in HIV-Infected Adults in CÔte D'Ivoire. <i>Antiviral Therapy</i> , 2007, 12, 543-551.	0.6	60
103	The Private Side of the Professional Man. <i>Journal of Investigative Dermatology</i> , 2006, 126, 533-535.	0.3	2
104	Cost-Effectiveness of an Intervention to Improve Adherence to Antiretroviral Therapy in HIV-Infected Patients. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2006, 43, S113-S118.	0.9	46
105	Expanded Screening for HIV in the United States – An Analysis of Cost-Effectiveness. <i>New England Journal of Medicine</i> , 2005, 352, 586-595.	13.9	504
106	A Randomized Controlled Trial to Enhance Antiretroviral Therapy Adherence in Patients with a History of Alcohol Problems. <i>Antiviral Therapy</i> , 2005, 10, 83-93.	0.6	100
107	Optimal Frequency of Cd4 Cell Count and HIV Rna Monitoring Prior to Initiation of Antiretroviral Therapy in HIV-Infected Patients. <i>Antiviral Therapy</i> , 2005, 10, 41-52.	0.6	14
108	Projecting the cost-effectiveness of adherence interventions in persons with human immunodeficiency virus infection. <i>American Journal of Medicine</i> , 2003, 115, 632-641.	0.6	97

#	ARTICLE	IF	CITATIONS
109	Lifetime Cost of HIV Care in France during the Era of Highly Active Antiretroviral Therapy. <i>Antiviral Therapy</i> , 2002, 7, 257-266.	0.6	37
110	The Cost Effectiveness of Combination Antiretroviral Therapy for HIV Disease. <i>New England Journal of Medicine</i> , 2001, 344, 824-831.	13.9	469
111	Cost-Effectiveness of Prenatal Screening for Postpartum Thyroiditis. <i>Journal of Women's Health and Gender-Based Medicine</i> , 2001, 10, 649-658.	1.7	16
112	Improving Participation in HIV Clinical Trials: Impact of a Brief Intervention. <i>HIV Clinical Trials</i> , 2001, 2, 205-212.	2.0	21
113	Use of Genotypic Resistance Testing To Guide HIV Therapy: Clinical Impact and Cost-Effectiveness. <i>Annals of Internal Medicine</i> , 2001, 134, 440.	2.0	215
114	Cost-Effectiveness of Earlier Initiation of Antiretroviral Therapy for Uninsured HIV-Infected Adults. <i>American Journal of Public Health</i> , 2001, 91, 1456-1463.	1.5	46
115	Preevaluation of Clinical Trial Data: The Case of Preemptive Cytomegalovirus Therapy in Patients with Human Immunodeficiency Virus. <i>Clinical Infectious Diseases</i> , 2001, 32, 783-793.	2.9	26
116	Performance Measures for Guidelines on Preventing Opportunistic Infections in Patients Infected with Human Immunodeficiency Virus. <i>Clinical Infectious Diseases</i> , 2000, 30, S85-S93.	2.9	6
117	The Cost-effectiveness of Preventing AIDS-Related Opportunistic Infections. <i>JAMA - Journal of the American Medical Association</i> , 1998, 279, 130.	3.8	218